Neumora Therapeutics Unveils Pipeline Advancements Targeting Major Brain Disorders

Neumora Therapeutics Inc. has released a corporate presentation outlining its progress in neuroscience drug development. The company highlighted a broad pipeline targeting major indications, including major depressive disorder, Alzheimer’s disease agitation, schizophrenia, obesity, Parkinson’s disease, and ALS. Key programs include Navacaprant, a KOR antagonist for major depressive disorder, currently progressing toward pivotal data readouts; NMRA-511, a V1aR antagonist for agitation in Alzheimer’s disease; and two M4 modulators, NMRA-861 and NMRA-898, for schizophrenia. The pipeline also features NMRA-215, an NLRP3 inhibitor for obesity and Parkinson’s disease, as well as additional candidates targeting Parkinson’s disease and ALS. Several clinical milestones are expected over the next year as the company advances its portfolio. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here